Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III